TGTX 250502 42.00P(TGTX250502P42000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

TGTX250502P42000

Watchlist

0.76
-0.97-56.07%

15min DelayClose Apr 29 16:00 ET

1.43High0.76Low

Intraday

5D
Daily

News

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
GlobeNewswire07:30 ET
TG Therapeutics (NasdaqCM:TGTX) Sees Profitable Turn With Strong Quarterly Earnings
Yahoo FinanceApr 28 14:00 ET
TG Therapeutics Insiders Sold US$2.5m Of Shares Suggesting Hesitancy
Simply Wall StApr 24 12:08 ET
TD Cowen Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $50
Moomoo NewsApr 24 02:41 ET · Ratings
SA Analyst Downgrades: TSLA, NFLX, VZ, CSCO, AVGO, TSM, CRWD, RTX
Seeking AlphaApr 23 13:12 ET
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $11
Moomoo NewsApr 18 03:32 ET · Ratings

Comments

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

$TG Therapeutics (TGTX.US)$
Game-Changing MS Treatment? BRIUMVI Single-Dose Trial Reveals Breakthrough Potential

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

$TG Therapeutics (TGTX.US)$
Game-Changing MS Treatment: BRIUMVI Reveals Exceptional Real-World Safety Profile

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

$TG Therapeutics (TGTX.US)$
Medical Journals Reveal Breakthrough: BRIUMVI Succeeds Where Other MS Treatments Fall Short

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

$TG Therapeutics (TGTX.US)$
How TG Therapeutics Transformed from Clinical-Stage to Profitable Biotech with 250% Revenue Growth

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

$TG Therapeutics (TGTX.US)$
Can BRIUMVI Succeed Where Other MS Treatments Failed? New Clinical Data Reveals Promising Results

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Read more